Current Report Filing (8-k)
2020年5月16日 - 2:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2020
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-54701
|
|
26-1579105
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
9460 Telstar Avenue, Suite 6
El Monte, California
|
|
91731
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (626)-401-9588
Not Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
YEWB
|
|
OTC Markets Group
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
The Corporation is unable to meet the filing
deadline for the filing of its Form 10-Q for the quarter ended March 31, 2020 due to circumstances related to COVID-19. Most of
the Company’s business is in China and so is its corporate office. Some of its businesses and offices were closed upon orders
of the local governments. Employees are prohibited from going into work. In view of these circumstances, we are unable to provide
our auditors and accountants with up to date financial records.
On March 4, 2020, the U.S. Securities and Exchange Commission (the
“SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange
Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020,
the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies
that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak
(the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section
13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to
file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations
13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C
and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
The Corporation is relying on SEC Releases
No. 34-88318 and No. 34-88465 to delay the filing of its Form 10-Q for the quarter ended March 31, 2020 for an extension on the
filing due date to 45 days after the original due date which is May 15, 2020, and will work diligently to comply with such requirements.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995
Information included in this Form 8-K may contain
forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other
factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company”
or “Registrant”), to be materially different from future results, performance or achievements expressed or implied
by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future
plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should,"
"expect," "anticipate," "estimate," "believe," "intend" or "project"
or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based
on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any
forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or
implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes
no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other
events occur in the future.
Signature(s)
Pursuant to the Requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned
hereunto duly authorized.
|
Yew Bio-Pharm Group, Inc.
|
|
|
Date: May 15, 2020
|
By:
|
/s/ Zhiguo Wang
|
|
|
Zhiguo Wang
|
|
|
President & Chief Executive Officer
|
Yew Bio Pharm (CE) (USOTC:YEWB)
過去 株価チャート
から 5 2024 まで 6 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Yew Bio Pharm Group Inc (CE) (その他OTC): 0 recent articles
その他のYew Bio-pharm Group, Inc.ニュース記事